These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38243170)

  • 1. Targeting the NAT10/NPM1 axis abrogates PD-L1 expression and improves the response to immune checkpoint blockade therapy.
    Qin G; Bai F; Hu H; Zhang J; Zhan W; Wu Z; Li J; Fu Y; Deng Y
    Mol Med; 2024 Jan; 30(1):13. PubMed ID: 38243170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NAT10/ac4C/FOXP1 Promotes Malignant Progression and Facilitates Immunosuppression by Reprogramming Glycolytic Metabolism in Cervical Cancer.
    Chen X; Hao Y; Liu Y; Zhong S; You Y; Ao K; Chong T; Luo X; Yin M; Ye M; He H; Lu A; Chen J; Li X; Zhang J; Guo X
    Adv Sci (Weinh); 2023 Nov; 10(32):e2302705. PubMed ID: 37818745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.
    Qin G; Wang X; Ye S; Li Y; Chen M; Wang S; Qin T; Zhang C; Li Y; Long Q; Hu H; Shi D; Li J; Zhang K; Zhai Q; Tang Y; Kang T; Lan P; Xie F; Lu J; Deng W
    Nat Commun; 2020 Apr; 11(1):1669. PubMed ID: 32245950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pumilio1 regulates NPM3/NPM1 axis to promote PD-L1-mediated immune escape in gastric cancer.
    Wang H; Zhou Z; Zhang J; Hao T; Wang P; Wu P; Su R; Yang H; Deng G; Chen S; Gu L; He Y; Zeng L; Zhang C; Yin S
    Cancer Lett; 2024 Jan; 581():216498. PubMed ID: 38029539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remodelin, a N-acetyltransferase 10 (NAT10) inhibitor, alters mitochondrial lipid metabolism in cancer cells.
    Dalhat MH; Mohammed MRS; Ahmad A; Khan MI; Choudhry H
    J Cell Biochem; 2021 Dec; 122(12):1936-1945. PubMed ID: 34605570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
    Fan P; Zhao J; Meng Z; Wu H; Wang B; Wu H; Jin X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):47. PubMed ID: 30709380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of glycolysis enhances the efficacy of immunotherapy via PDK-mediated upregulation of PD-L1.
    Zhang R; Mao G; Tang Y; Li C; Gao Y; Nie W; Song T; Liu S; Zhang P; Tao K; Li W
    Cancer Immunol Immunother; 2024 Jun; 73(8):151. PubMed ID: 38832951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remodelin, an inhibitor of NAT10, could suppress hypoxia-induced or constitutional expression of HIFs in cells.
    Wu Y; Cao Y; Liu H; Yao M; Ma N; Zhang B
    Mol Cell Biochem; 2020 Sep; 472(1-2):19-31. PubMed ID: 32529496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
    Chen XY; Li B; Wang Y; Jin J; Yang Y; Huang LH; Yang MD; Zhang J; Wang BY; Shao ZM; Ni T; Huang SL; Hu XC; Tao ZH
    Cancer Commun (Lond); 2023 Sep; 43(9):1003-1026. PubMed ID: 37434394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of
    Ma N; Liu H; Wu Y; Yao M; Zhang B
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Helicobacter pylori-induced NAT10 stabilizes MDM2 mRNA via RNA acetylation to facilitate gastric cancer progression.
    Deng M; Zhang L; Zheng W; Chen J; Du N; Li M; Chen W; Huang Y; Zeng N; Song Y; Chen Y
    J Exp Clin Cancer Res; 2023 Jan; 42(1):9. PubMed ID: 36609449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
    Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
    J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint Blockade.
    Tseng YJ; Lee CH; Chen WY; Yang JL; Tzeng HT
    J Invest Dermatol; 2021 Nov; 141(11):2690-2698.e6. PubMed ID: 34000287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
    Wang Z; Wu X
    Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetyltransferase NAT10 regulates the Wnt/β-catenin signaling pathway to promote colorectal cancer progression via ac
    Jin C; Wang T; Zhang D; Yang P; Zhang C; Peng W; Jin K; Wang L; Zhou J; Peng C; Tan Y; Ji J; Chen Z; Sun Q; Yang S; Tang J; Feng Y; Sun Y
    J Exp Clin Cancer Res; 2022 Dec; 41(1):345. PubMed ID: 36522719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies.
    Liao L; Xu H; Zhao Y; Zheng X
    Front Med; 2023 Oct; 17(5):805-822. PubMed ID: 37897562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma.
    Jiang G; Shi L; Zheng X; Zhang X; Wu K; Liu B; Yan P; Liang X; Yu T; Wang Y; Cai X
    Aging (Albany NY); 2020 Jun; 12(12):11466-11484. PubMed ID: 32579541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.